Targeting HCPs in the UK: ABPI Code Basics for Media Teams
What US teams need to know about promoting medicines to UK HCPs: no public promotion of Rx medicines, the ABPI Code, certification, and data rules.
The short answer
In the UK, prescription-only medicines cannot be advertised to the public, so promotion is aimed only at healthcare professionals and other relevant decision makers. Industry self-regulation under the ABPI Code, administered by the PMCPA, adds rules on content, certification by qualified signatories, digital channels, and transparency of payments. Segmenting HCPs is allowed, but it must use lawfully processed data under UK data protection law, and electronic marketing often requires consent.
US pharma teams expanding into the UK often assume the HCP playbook transfers. Some of it does. The differences in public promotion, certification, data protection, and self-regulation are large enough that local expertise is essential. This article is an orientation, not legal advice.
The big difference: no public promotion of prescription-only medicines
In the UK, prescription-only medicines cannot be advertised to the public. Promotion targets healthcare professionals and appropriate administrative staff. Disease awareness campaigns for the public are allowed but must not promote a specific medicine, directly or indirectly.
The MHRA's Blue Guide explains the legal framework.
The ABPI Code and PMCPA
The ABPI Code of Practice sets detailed industry rules. Key themes:
- Content standards. Accurate, balanced, fair, and consistent with the product's marketing authorization.
- Certification. Promotional material must be certified by appropriately qualified signatories before use.
- Digital communications. Rules for websites, social media, and digital channels, including restricting promotional content to HCP audiences.
- Interactions with HCPs. Rules on meetings, hospitality, and payments.
- Transparency. Disclosure of transfers of value to HCPs and organizations.
The PMCPA administers the Code and publishes case reports, which are useful learning material.
HCP segmentation and data
- Data about HCPs is personal data under UK data protection law. Processing needs a lawful basis.
- Electronic marketing, such as email, often requires consent under UK rules.
- Segmenting by prescribing behavior depends on the data source and how it was collected.
Work with local data protection and compliance teams before building targeting.
Digital media to UK HCPs
- Promotional content must be restricted to HCP audiences, typically through verified access.
- Programmatic targeting of HCPs on the open web needs careful verification and controls.
- Social media promotion is limited and closely governed.
Practical differences from the US
| Area | US | UK |
|---|---|---|
| Public promotion of Rx medicines | Allowed with FDA rules | Prohibited |
| Main promotion rules | FDA law and guidance | Law plus ABPI Code self-regulation |
| Material approval | Company MLR process | Certification by qualified signatories |
| HCP data | Sector rules, state laws | UK data protection law |
| Transparency | Open Payments | Industry disclosure under the Code |
Common mistakes
- Running US HCP creative in the UK without local certification.
- Using US-sourced HCP data for UK targeting.
- Open-web programmatic without HCP verification.
- Disease awareness that points to a product.
Practical takeaway
Before any UK HCP campaign, confirm three things with local experts: the material is certified under the Code, the HCP data has a lawful basis for this use, and digital placements restrict promotional content to verified HCPs.
Frequently asked questions
Can prescription medicines be advertised to the public in the UK?
No. Advertising prescription-only medicines to the public is prohibited. Disease awareness campaigns are allowed within rules.
What is the ABPI Code?
The Association of the British Pharmaceutical Industry's Code of Practice for the promotion of medicines and interactions with HCPs and others, administered by the PMCPA.
Can UK HCPs be targeted by prescribing volume?
Segmentation is possible, but the data must be lawfully obtained and processed under UK data protection law, and the approach must comply with the ABPI Code. Check with local compliance.
Sources
- Prescription Medicines Code of Practice Authority (PMCPA)
- MHRA, The Blue Guide: Advertising and Promoting Medicines in the UK
- EFPIA
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.